glp 1 skin pain Patient Buzz: Care After GLP-1 Weight Loss | The Expert Weighs In A Closer Look at the

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications originally developed for type 2 diabetes management, with some now approved for chronic weight management

Conclusion GLP-1 drugs are catalyzing profound shifts in consumer behavior, spanning food, beauty, fitness, travel, and retail

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

However, results can vary depending on your body and level of deficiency